Advertisement

Topics

3 Years Long-time Follow up of Kaletra Therapy

2014-07-23 21:09:53 | BioPortfolio

Summary

Long-term observation of therapy-naïve patients under Kaletra therapy.

Description

Long-term observation of therapy-naïve patients under Kaletra therapy. The study is investigating the following questions:

- Are there any resistance developments against Kaletra?

- If yes, how long does it take to develop the resistance?

- Which mutations are being selected?

- After virologic failure of Kaletra what other therapy regimens are effective?

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Human Immunodeficiency Virus

Intervention

Lopinavir/Ritonavir (Kaletra)

Location

Site Reference ID/Investigator# 5299
Berlin
Germany
10719

Status

Active, not recruiting

Source

Abbott

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:09:53-0400

Clinical Trials [1609 Associated Clinical Trials listed on BioPortfolio]

3 Years/5 Years Long-time Follow-up of Kaletra After Failure of Primary Therapy

Development of resistance to protease inhibitors in patients under Kaletra as first or second-line therapy.

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-in...

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Usage, dosing, tolerability, and effectiveness of Kaletra tablets in Human Immunodeficiency Virus-infected patients.

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same d...

Lopinavir/Ritonavir (Kaletra)PK

The objective of this study is to compare the pharmacokinetics of lopinavir tablets administered to pediatric patients as either whole or crushed tablets. The study is a randomized,open-la...

PubMed Articles [12888 Associated PubMed Articles listed on BioPortfolio]

Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.

In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonav...

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

The emergence of drug-resistant HIV from a wide-spread anti-viral chemotherapy targeting HIV protease in the past decades is unavoidable and provides a challenge to develop alternative inhibitors. We ...

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral triple treatment...

Plasma metabolic changes in Chinese HIV-infected patients receiving lopinavir/ritonavir based treatment: Implications for HIV precision therapy.

The goal of this study is to profile the metabolic changes in the plasma of HIV patients receiving lopinavir/ritonavir (LPV/r)-based highly active antiretroviral therapy (HAART) relative to their trea...

Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.

To evaluate changes in pro-atherosclerotic biomarkers and endothelial function in patients initiating two different PI-based regimens as part of ART.

Medical and Biotech [MESH] Definitions

Proteins encoded by the NEF GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the VIF GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the REV GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the VPR GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Proteins encoded by the TAT GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

More From BioPortfolio on "3 Years Long-time Follow up of Kaletra Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial